Early initiation of ezetimibe within 12 weeks of myocardial infarction was associated with reduced risks of major adverse cardiovascular events and cardiovascular death compared with delayed or no ezetimibe use, according to a nationwide analysis. Using a clone-censor-weight approach, the study found that early combination therapy with statins and ezetimibe should be implemented as standard care in MI care pathways to improve prognosis.

Source:  Journal of the American College of Cardiology